Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $31.34 USD
Change Today +0.36 / 1.16%
Volume 77.1K
PODD On Other Exchanges
As of 10:17 AM 06/30/15 All times are local (Market data is delayed by at least 15 minutes).

insulet corp (PODD) Snapshot

Previous Close
Day High
Day Low
52 Week High
12/8/14 - $47.97
52 Week Low
05/1/15 - $24.95
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for INSULET CORP (PODD)

insulet corp (PODD) Related Bloomberg News

View More Bloomberg News

insulet corp (PODD) Related Businessweek News

No Related Businessweek News Found

insulet corp (PODD) Details

Insulet Corporation develops, manufactures, and sells insulin infusion systems for people with insulin-dependent diabetes in the United States. The company offers OmniPod Insulin Management System (OmniPod System), which consists of the OmniPod, a disposable insulin infusion device that integrates an infusion set, automated cannula insertion, insulin reservoir, drive mechanism, and batteries; and personal diabetes manager, a handheld wireless device. It also sells blood glucose testing supplies, insulin pumps, pump supplies, pharmaceuticals, and other products for the management and treatment of diabetes. The company sells and markets its OmniPod System to diabetes practitioners, academic medical centers, clinics, people with insulin-dependent diabetes, third-party payors, and government agencies, as well as third-party distributors. Insulet Corporation was founded in 2000 and is headquartered in Billerica, Massachusetts.

519 Employees
Last Reported Date: 02/26/15
Founded in 2000

insulet corp (PODD) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $182.5K
Chief Operating Officer
Total Annual Compensation: $453.4K
General Counsel and Secretary
Total Annual Compensation: $265.0K
Executive Vice President of Human Resources a...
Total Annual Compensation: $49.7K
Compensation as of Fiscal Year 2014.

insulet corp (PODD) Key Developments

Brower Piven Announces Class Action Lawsuit Against Insulet Corp

Brower Piven announced that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of purchasers of Insulet Corp. securities during the period between February 27, 2013 and April 30, 2015, inclusive. The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants’ failure to disclose during the Class Period that the company was experiencing slower demand for its products and experiencing problems with its sales and marketing efforts. According to the complaint, following the company’s April 30, 2015 disclosure of its first quarter 2015 financial results, including a statement that deliveries and shipments planned for the first quarter were now expected to be realized during the remainder of 2015, the value of Insulet shares declined significantly.

Glancy Prongay & Murray LLP Files Lawsuit Against Insulet Corporation

Glancy Prongay & Murray LLP, representing investors of Insulet Corp., has filed a class action lawsuit in the United States District Court for the District of Massachusetts on behalf of a class comprising purchasers of Insulet securities between February 27, 2013 and April 30, 2015, inclusive. The complaint alleges that Defendants made false and/or misleading statements, as well as failed to disclose material adverse facts about the company’s business, operations, and prospects. Specifically, Defendants failed to disclose: that the company was experiencing slower demand for its products; that the company was facing issues with its sales and marketing efforts; that, as a result, the company experienced unevenness in its financial performance; and that, as a result of the foregoing, Defendants’ positive statements about the company’s business, operations, and prospects lacked a reasonable basis. As a result of Defendants’ wrongful acts and omissions, and the precipitous decline in the market value of the company’s securities after disclosing the decline in its revenues, Plaintiff and other class members have suffered significant losses and damages.

Insulet Corporation Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Reaffirms Earnings Guidance for the Year Ending December 31, 2015; Provides Earnings Guidance for the Second Quarter of 2015

Insulet Corporation reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company's revenue decreased 11% to $61.2 million, compared with $69.2 million in the first quarter of 2014. Operating loss was $8.6 million, compared with an operating loss of $1.9 million in the first quarter of 2014. This result was primarily driven by a 19% increase in operating expenses to $41.4 million compared with $34.7 million in the prior year. Net loss was $11.8 million, or $0.21 per share, compared with net loss of $6.1 million, or $0.11 per share, in the first quarter of 2014. Loss before income taxes was $11.782 million against $6.079 million a year ago. For the year ending December 31, 2015, the company is reaffirming its revenue guidance of $305 to $320 million. For the second quarter of 2015, the company is expecting revenue to be in the range of $67 to $70 million.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PODD:US $31.33 USD +0.35

PODD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $49.23 USD +0.22
DexCom Inc $79.84 USD +0.74
Smiths Group PLC 1,131 GBp +4.00
Takeda Pharmaceutical Co Ltd ¥5,911 JPY +75.00
Tandem Diabetes Care Inc $11.01 USD +0.16
View Industry Companies

Industry Analysis


Industry Average

Valuation PODD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 6.4x
Price/Book 22.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 5.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INSULET CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at